At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
RBM-007drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating RBM-007 for Exudative Age-related Macular Degeneration. Completed, enrolled 40 participants across 6 sites.
Detailed Summary
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedNov 2020
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedNov 23, 2020
Enrollment StartNov 3, 2020
Primary CompletionNov 19, 2021
Study CompletionDec 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.6 years ago
Interventions
RBM-007drug
Intravitreal injection